Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Bücher
Zeitschriften
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
SLX-Digitalkonferenz: Zukunftswerkstatt 2024

Mehr Umsatz mit Top-Kontakten

Am 7. Mai erfahren Sie, wie Vertriebsteams Leadgenerierung, Leadnurturing und Leadstrategien effizient steuern können.
Erweiterte Suche
Anmelden
nach oben
Quality of Life Research
Erschienen in: Quality of Life Research 4/2019

21.11.2018

Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1

verfasst von: James W. Varni, Kavitha Nutakki, Nancy L. Swigonski

Erschienen in: Quality of Life Research | Ausgabe 4/2019

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Objectives

The aim was to investigate pain, skin sensations symptoms and patient self-reported, and parent proxy-reported cognitive functioning as predictors of generic health-related quality of life (HRQOL) in pediatric patients with Neurofibromatosis Type 1 (NF1) from the perspectives of patients and parents.

Methods

The Pain, Skin Itch Bother, Skin Sensations, and Cognitive Functioning Scales from the PedsQL™ Neurofibromatosis Type 1 Module and the PedsQL™ Generic Core Scales were completed in a multi-site national study by 323 patients and 335 parents. Patients were 5–25 years of age. Pain and skin symptoms and cognitive functioning were tested for bivariate and multivariate linear associations with generic HRQOL.

Results

Pain, skin itch bother, skin sensations, and cognitive functioning were associated with decreased HRQOL in bivariate analyses (Ps < 0.001). In predictive analytics models, utilizing hierarchical multiple regression analyses controlling for demographic covariates, pain, skin itch bother, skin sensations, and cognitive functioning as a group accounted for 61 percent of the variance in patient-reported generic HRQOL (P < 0.001), reflecting a large effect size. For parent proxy-report, the predictor variables as a group accounted for 53% of the variance in generic HRQOL.

Conclusions

Pain, skin symptoms, and patient self-reported and parent proxy-reported cognitive functioning are key predictors of generic HRQOL in pediatric patients with NF1. Delineating NF1-specific symptoms and cognitive functioning as high-priority predictors from the patient and parents perspective enhances a family-centered approach in clinical research, clinical trials, and clinical practice intended to improve the global generic HRQOL of pediatric patients with NF1.
Vorheriger Artikel Health-related quality of life assessment among people living with HIV in Rio de Janeiro, Brazil: a cross-sectional study
Nächster Artikel Association between medication adherence and quality of life of patients with diabetes and hypertension attending primary care clinics: a cross-sectional survey

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Literatur
1.
Monroe, C. L., Dahiya, S., & Gutmann, D. H. (2017). Dissecting clinical heterogeneity in Neurofibromatosis Type 1. Annual Review of Pathology, 12, 53–74.CrossRefPubMed
2.
Blakeley, J. O., & Plotkin, S. R. (2016). Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro-Oncology, 18, 624–638.CrossRefPubMedCentralPubMed
3.
Vranceanu, A. M., Merker, V. L., Park, E. R., & Plotkin, S. R. (2015). Quality of life among children and adolescents with Neurofibromatosis 1: A systematic review of the literature. Journal of Neuro-Oncology, 122, 219–228.CrossRefPubMed
4.
Nutakki, K., Hingtgen, C. M., Monahan, P., Varni, J. W., & Swigonski, N. L. (2013). Development of the adult PedsQL Neurofibromatosis Type 1 Module: Initial feasibility, reliability and validity. Health and Quality of Life Outcomes, 11, 21.CrossRefPubMedCentralPubMed
5.
Nutakki, K., Varni, J. W., Steinbrenner, S., Draucker, C. B., & Swigonski, N. L. (2017). Development of the Pediatric Quality of Life Inventory Neurofibromatosis Type 1 Module items for children, adolescents and young adults: Qualitative methods. Journal of Neuro-Oncology, 132, 135–143.CrossRefPubMed
6.
Draucker, C. B., Nutakki, K., Varni, J. W., & Swigonski, N. L. (2017). The health-related quality of life of children, adolescents, and young adults with neurofibromatosis type 1 and their families: Analysis of narratives. Journal for Specialists in Pediatric Nursing, 22, e12174.CrossRef
7.
Nutakki, K., Varni, J. W., & Swigonski, N. L. (2018). PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: Feasibility, reliability, and validity. Journal of Neuro-Oncology, 137, 337–347.CrossRefPubMed
8.
Varni, J. W., Seid, M., & Kurtin, P. S. (2001). PedsQL™ 4.0: Reliability and validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in healthy and patient populations. Medical Care, 39, 800–812.CrossRefPubMed
9.
Varni, J. W., & Limbers, C. A. (2009). The PedsQL™ 4.0 Generic Core Scales young adult version: Feasibility, reliability and validity in a university student population. Journal of Health Psychology, 14, 611–622.CrossRefPubMed
10.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale: Erlbaum.
11.
Cohen, J., Cohen, P., West, S. G., & Aiken, L. S. (2003). Applied multiple regression/correlation analysis for the behavioral sciences (3rd ed.). Mahwah: Erlbaum.
12.
Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16, 297–334.CrossRef
13.
Créange, A., Zeller, J., Rostaing-Rigattieri, S., Brugières, P., Degos, J. D., Revuz, J., & Wolkenstein, P. (1999). Neurological complications of neurofibromatosis type 1 in adulthood. Brain, 122, 473–481.CrossRefPubMed
14.
DiMario, F. J., & Langshur, S. (2000). Headaches in patients with neurofibromatosis-1. Journal of Child Neurology, 15, 235–238.CrossRefPubMed
15.
Bardo-Brouard, P., Luizard, C., Valeyrie-Allanore, L., Goujon, C., Do, B., Colin, A., Wolkenstein, P., & Paul, M. (2018). High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: A case series. Current Medical Research and Opinion, 34, 887–891.CrossRefPubMed
16.
Brenaut, E., Nizery-Guermeur, C., Audebert-Bellanger, S., Ferkal, S., Wolkenstein, P., Misery, L., & Abasq-Thomas, C. (2016). Clinical characteristics of pruritus in neurofibromatosis 1. Acta Dermato-Venereologica, 96, 398–399.CrossRefPubMed
17.
Khosrotehrani, K., Bastuji-Garin, S., Riccardi, V. M., Birch, P., Friedman, J. M., & Wolkenstein, P. (2005). Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients. American Journal of Medical Genetics Part A, 132A, 49–53.CrossRefPubMed
18.
Ozonoff, S. (1999). Cognitive impairment in neurofibromatosis type 1. American Journal of Medical Genetics, 89, 45–52.CrossRefPubMed
19.
Hyman, S. L., Shores, A., & North, K. N. (2005). The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology, 65, 1037–1044.CrossRefPubMed
20.
Schwetye, K. E., & Gutmann, D. H. (2014). Cognitive and behavioral problems in children with neurofibromatosis type 1: Challenges and future directions. Expert Review of Neurotherapeutics, 14, 1139–1152.CrossRefPubMed
21.
Payne, J. M., Hyman, S. L., Shores, E. A., & North, K. N. (2011). Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior. Child Neuropsychology, 17, 313–329.CrossRefPubMed
22.
Varni, J. W., Limbers, C. A., & Burwinkle, T. M. (2007). Impaired health-related quality of life in children and adolescents with chronic conditions: A comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL™ 4.0 Generic Core Scales. Health and Quality of Life Outcomes, 5(43), 1–15.CrossRefPubMedCentralPubMed
23.
Nguyen, R., Kluwe, L., Fuensterer, C., Kentsch, M., Friedrich, R. E., & Mautner, V. F. (2011). Plexiform neurofibromas in children with neurofibromatosis type 1: Frequency and associated clinical deficits. Journal of Pediatrics, 159, 652–655.CrossRefPubMed
24.
Varni, J. W., Limbers, C. A., & Newman, D. A. (2009). Using factor analysis to confirm the validity of children’s self-reported health-related quality of life across different modes of administration. Clinical Trials, 6, 185–195.CrossRefPubMed
25.
Ater, J. L., Xia, C., Booth, M. M. C., Freyer, T. N., Packer, D. R., Sposto, R. J., Vezina, R., G., & Pollack, I. F. (2016). Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children’s Oncology Group. Cancer, 122, 1928–1936.CrossRefPubMed
Metadaten
Titel
Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1
verfasst von
James W. Varni
Kavitha Nutakki
Nancy L. Swigonski
Publikationsdatum
21.11.2018
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 4/2019
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-2055-5

Weitere Artikel der Ausgabe 4/2019

Quality of Life Research 4/2019 Zur Ausgabe

Review

Individualized health-related quality of life instrument Measure Yourself Medical Outcome Profile (MYMOP) and its adaptations: a critical appraisal

OriginalPaper

Effects of self-esteem and stress on self-assessed health: a Swiss study from adolescence to early adulthood

Brief Communication

Trials with proxy-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR)

OriginalPaper

Developmental coordination disorder: the impact on the family

OriginalPaper

Is it possible to determine the level of functional impairment that distinguishes the patients with ADHD from those without ADHD?

OriginalPaper

Health-related quality of life predicted subsequent health care resource utilization in patients with active cancer